AstraZeneca Pharma India shares traded in the green and 6% higher on 21 December after the company said that it will launch its breast cancer drug, Enhertu, in January 2024 in India.

In its regulatory filing, the company said, “Enhertu is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen.”

In May, the company also received import and market permission in Form CT-20 from the Drugs Controller General of India for Tanstuzumab deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion (Enhertu).

In its quarterly report for July-September, the company reported a 60.8% year-on-year increase in its consolidated net profit to Rs 52.4 crore. The revenue during the quarter stood at Rs 311 crore, which is a 31.7% YoY increase from the number reported in the same quarter last year.

AstraZeneca Pharma India is a subsidiary of AstraZeneca Plc, UK, and handles the company’s manufacturing, selling, and marketing activities in India.

At 3:30 pm, the shares of AstraZeneca Pharma India were trading 2.90% higher at Rs 4,750 on NSE.